Oleaginous pharmaceutical and cosmetic foam
First Claim
Patent Images
1. A foamable pharmaceutical or cosmetic composition, comprising:
- a solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, wherein the PEG or PEG derivative is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one active agent.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.
-
Citations
121 Claims
-
1. A foamable pharmaceutical or cosmetic composition, comprising:
-
a solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, wherein the PEG or PEG derivative is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one active agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 59, 60, 121)
-
-
56. A foamable pharmaceutical or cosmetic carrier composition for dermatological use, comprising:
-
a solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, wherein the PEG or PEG derivative is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition;
at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; and
at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
-
-
57. A composition, comprising:
-
a polyethylene glycol (PEG) or PEG derivative and mixtures thereof, wherein the PEG or PEG derivative is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one agent selected from the group consisting of an antinfective agent, a keratolytically active agent, a vasoactive agent and a retinoid.
-
-
58. A composition, comprising:
-
a polyethylene glycol (PEG) or PEG derivative and mixtures thereof, wherein the PEG or PEG derivative is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one anti-inflammatory or antiallergic agent, wherein said agent reduces the occurrence of pro-inflammatory cytokines and/or inhibits the effect of pro-inflammatory cytokines.
-
-
61. A foamable pharmaceutical or cosmetic composition, comprising:
-
a solvent comprising propylene glycol, wherein the propylene glycol is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one active agent. - View Dependent Claims (62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)
-
-
116. A foamable pharmaceutical or cosmetic carrier composition for dermatological use, comprising:
-
a solvent comprising propylene glycol, wherein the propylene glycol is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition;
at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; and
at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam. - View Dependent Claims (119, 120)
-
-
117. A composition, comprising:
-
a solvent comprising propylene glycol, wherein the propylene glycol is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one active agent selected from the group consisting of an antinfective agent, a keratolytically active agent, a vasoactive agent and a retinoid.
-
-
118. A composition, comprising:
-
a solvent comprising propylene glycol, wherein the propylene glycol is present at a concentration of about 70% to about 96.5% by weight of the total composition;
a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; and
a therapeutically effective amount of at least one anti-inflammatory or antiallergic agent, wherein said agent reduces the occurrence of pro-inflammatory cytokines and/or inhibits the effect of pro-inflammatory cytokines.
-
Specification